# Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients

> **NCT06830421** · PHASE3 · RECRUITING · sponsor: **University Hospital Freiburg** · enrollment: 340 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** R-MP and Procarbazine maintenance
- **DRUG:** R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT

## Key facts

- **NCT ID:** NCT06830421
- **Lead sponsor:** University Hospital Freiburg
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-09
- **Primary completion:** 2029-08-31
- **Final completion:** 2031-08-31
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2025-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06830421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06830421, "Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06830421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*